What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors

Related Articles

What Do UNFI's Mixed Q2 Results Really Mean for Investors

5 months ago

What Do AEVA's Insider Sales Really Mean for Investors

5 months ago

Aftermath Silver: What Do Berenguela's Latest Drill Results Mean for Investors

5 months ago

What Does a CEO's Stock Purchase Really Mean for Investors

4 months ago

Category

You may also like

Stock News•4 days ago

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma's psychedelic platform, spanning MDD and GAD, approaches a phase III catalyst for HLP003. Early data suggest efficacy, but small trials limit validation. Positive results could reduce its...

HLP

Share

Stock News•2 weeks ago

MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)

MoonLake Immunotherapeutics saw 2,707 call options traded Monday, up 142% from the typical 1,118 daily volume, after unusual options activity and an insider sale by Kristian Reich.

MLTX

Share

Stock News•2 weeks ago

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MoonLake's sonelokimab met all Phase 3 IZAR-1 endpoints at Week 16, with ACR50 at 42.1% in bio-naïve PsA patients, after positive topline results. The company holds $537M cash, with runway to mid-2028...

MLTX

Share

Stock News•1 months ago

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

Satellos Bioscience (NASDAQ:MSLE) reported six-month interim data from its TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy, boosting confidence in the drug candidate.

MSLE

Share